Endoplasmic reticulum-targeting activatable nanophotosensitizers for hypoxia relief and enhanced photodynamic therapy

• Published in: Chemical science (Cambridge) Vol. 16; no. 24; pp. 199 - 1917
• Main Authors: Diao, Shanchao, He, Xiaowen, Wu, Ying, Yin, Likun, Huang, Yuxin, Zhou, Wen, Xie, Chen, Fan, Quli
• Format: Journal Article
• Language: English
• Published: England Royal Society of Chemistry 18.06.2025; The Royal Society of Chemistry
• Subjects: Chemistry; Copolymers; Effectiveness; Endoplasmic reticulum; Hydrogen peroxide; Hypoxia; In vivo methods and tests; Nanoparticles; Photodynamic therapy; Tumors
• DOI: 10.1039/d5sc00534e
• ISSN: 2041-6520

Photodynamic therapy (PDT) is a promising cancer therapeutic modality. However, the specific targeting capability of conventional photosensitizers is relatively low, which significantly suppresses the efficacy of PDT. In this study, an endoplasmic reticulum (ER)-targeting nanophotosensitizer (TPPa-Y NP) was designed and prepared for enhanced PDT. TPPa-Y NPs are prepared by encapsulating an ER-targeting pheophorbide-a (TPPa) and a hypoxia inducible factor 1α (HIF-1α) inhibitor (YC-1) with a hydrogen peroxide (H 2 O 2 )-responsive amphiphilic copolymer (PEG-PMPAP). After internalization into tumor cells, TPPa-Y NPs may rapidly dissociate and release both TPPa and YC-1. TPPa can target ER, which leads to an enhancement in its fluorescence signal and PDT efficacy. On the other hand, YC-1 may effectively inhibit the overexpressed HIF-1α and alleviate tumor hypoxia, which can further enhance the PDT efficacy of TPPa. Both in vitro and in vivo studies demonstrate that TPPa-Y NPs have a better anticancer effect than the nanoparticles without YC-1 (TPPa NPs). Therefore, this study provides a smart nanophotosensitizer, which is able to target ER and alleviate hypoxia for PDT efficacy enhancement. This work developed endoplasmic reticulum (ER)-targeting activatable nanophotosensitizers, which can selectively release ER-targeting photosensitizers and YC-1 within tumor cells for enhanced photodynamic therapy and hypoxia relief, respectively.